Breaking News Instant updates and real-time market news.

CYH

Community Health

$9.10

0.22 (2.48%)

, HCA

HCA Healthcare

$87.72

-0.48 (-0.54%)

20:05
04/13/17
04/13
20:05
04/13/17
20:05

Trump administration issues proposal to 'stabilize' Obamacare markets

The Health and Human Services Department has published a proposed rule that "would help stabilize the individual and small group markets. This proposed rule would amend standards relating to special enrollment periods, guaranteed availability, and the timing of the annual open enrollment period in the individual market for the 2018 plan year; standards related to network adequacy and essential community providers for qualified health plans; and the rules around actuarial value requirements." Publicly traded companies in the hospital, healthcare, and insurance space include Community Health Systems (CYH), HCA (HCA), LifePoint (LPNT), Tenet (THC), Universal Health Services (UHS), UnitedHealth (UNH), Kindred (KND), Ventas (VTR), Aetna (AET), Anthem (ANTM), Cigna (CI) and Humana (HUM). Reference Link

CYH

Community Health

$9.10

0.22 (2.48%)

HCA

HCA Healthcare

$87.72

-0.48 (-0.54%)

LPNT

LifePoint

$63.95

-0.4 (-0.62%)

THC

Tenet

$17.48

-0.13 (-0.74%)

UHS

Universal Health

$121.81

-1.25 (-1.02%)

UNH

UnitedHealth

$164.96

-0.6 (-0.36%)

KND

Kindred Healthcare

$7.75

-0.05 (-0.64%)

VTR

Ventas

$65.06

-0.58 (-0.88%)

AET

Aetna

$128.63

-0.45 (-0.35%)

ANTM

Anthem

$164.99

-1.44 (-0.87%)

CI

Cigna

$150.41

-0.18 (-0.12%)

HUM

Humana

$211.80

-1.19 (-0.56%)

  • 18

    Apr

  • 20

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 28

    Apr

  • 28

    Apr

  • 02

    May

  • 04

    May

  • 05

    May

  • 16

    May

  • 18

    May

  • 18

    May

  • 24

    May

  • 06

    Jun

  • 13

    Jun

CYH Community Health
$9.10

0.22 (2.48%)

02/27/17
WEDB
02/27/17
NO CHANGE
Target $95
WEDB
Outperform
Masimo price target raised to $95 from $85 at Wedbush
Wedbush analyst Tao Levy noted that flu activity remains elevated, which could have positive implications for Masimo's (MASI) pulse oximetry franchise in Q1. The analyst, who raised his price target on Masimo shares to $95 from $85, also noted that recent management comments from earnings calls held by Teleflex (TFX) and Community Health Systems (CYH) confirms his belief that healthcare utilization increased in Q1 from the same quarter of last year. He keeps an Outperform rating on Masimo shares.
03/01/17
PIPR
03/01/17
DOWNGRADE
Target $7
PIPR
Underweight
Community Health downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Sarah James downgraded Community Health Systems to Underweight saying the 56% rally over the past four weeks is "excessive." Community Health now trades in parity with industry leader HCA Holdings (HCA) despite a weaker balance sheet, James tells investors in a research note. She believes Community's high debt levels are limiting the company's long-term growth prospects. James cut her price target for the shares to $7 from $10.
04/05/17
DBAB
04/05/17
INITIATION
Target $11
DBAB
Hold
Community Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg started Community Health Systems with a Hold rating and $11 price target.
03/13/17
MZHO
03/13/17
NO CHANGE
Target $7.5
MZHO
Neutral
Community Health unlikely to be taken private by Shanda, says Mizuho
Mizuho analyst Sheryl Skolnick noted that Tianqiao Chen and the Shanda group of entities, which are the largest shareholder of Community Health Systems, changed their filing status to active from passive. However, Community Health's high leverage make a go-private deal unlikely and put a limit on her "enthusiasm and the upward move of the stock" on the news of an activist shareholder, Skolnick tells investors. She keeps a Neutral rating on Community Health shares.
HCA HCA Healthcare
$87.72

-0.48 (-0.54%)

04/04/17
DBAB
04/04/17
INITIATION
DBAB
Buy
HCA Holdings initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated HCA Holdings with a Buy rating and a $103 price target, noting the company's significant market share in some of the fastest growing markets in the U.S., strong free cash flow, and history of returning capital to shareholders.
03/27/17
03/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Adobe (ADBE) upgraded to Buy from Neutral at BTIG. 2. Best Buy (BBY) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying store closures from hhgregg and potentially Sears (SHLD) could lift Best Buy's comp sales by 2%, Keith tells investors in a research note. Further, the upcoming iPhone and Samsung Galaxy Note launches should bring a "strong smartphone upgrade cycle," the analyst contends. 3. HCA Holdings (HCA) and Universal Health (UHS) were upgraded to Buy from Neutral at Mizuho. 4. Weatherford (WFT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Judson Bailey citing greater confidence in improving operations with the hire of CEO Mark McCollum and the formation of the OneStim joint venture. 5. Brookdale Senior Living (BKD) upgraded to Buy from Hold at Jefferies with analyst Brian Tanquilut citing an improved risk/reward following the recent pullback in the shares. The analyst sees a greater than 50% probability that Brookdale's ongoing sale process results in a deal, but thinks the stock can reach $14.50 even without a takeout. He upped his price target for the shares to $16.50 from $14. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/17
MZHO
03/27/17
UPGRADE
Target $98
MZHO
Buy
HCA Holdings upgraded to Buy following ACA repeal failure at Mizuho
As previously reported, Mizuho upgraded HCA Holdings to Buy from Neutral with a $98 price target. Analyst Sheryl Skolnick said the failure of the GOP to move on ACA repeal out of the House, will result in the continuation of the important benefit of Medicaid expansion and without a near-or medium-term threat of block grants. Additionally, the analyst views HCA Holdings as undervalued given strong volumes and free cash flow.
03/27/17
MZHO
03/27/17
UPGRADE
MZHO
Buy
HCA Holdings upgraded to Buy from Neutral at Mizuho
LPNT LifePoint
$63.95

-0.4 (-0.62%)

04/04/17
DBAB
04/04/17
INITIATION
DBAB
Hold
LifePoint initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated LifePoint with a Hold rating and a $68 price target.
11/11/16
FBCO
11/11/16
DOWNGRADE
FBCO
Neutral
LifePoint downgraded to Neutral from Outperform at Credit Suisse
11/11/16
FBCO
11/11/16
DOWNGRADE
Target $60
FBCO
Neutral
LifePoint downgraded to Neutral following Trump win at Credit Suisse
As previously reported, Credit Suisse downgraded LifePoint to Neutral from Outperform and lowered its price target to $60 from $70. Analyst Scott Fidel said LifePoint has significantly benefited from the Affordable Care Act and sees significant uncertainty ahead following Trump's victory and the Republican sweep. The analyst said 8%-10% of LifePoint's EBITDA could be at risk, which could be partially offset by improvements at its recently acquired facilities.
01/03/17
PIPR
01/03/17
INITIATION
Target $62
PIPR
Neutral
LifePoint initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Sarah James initiated LifePoint with a Neutral and a $62 price target.
THC Tenet
$17.48

-0.13 (-0.74%)

04/04/17
DBAB
04/04/17
INITIATION
Target $28
DBAB
Buy
Tenet initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated Tenet with a Buy and a $28 price target saying the company has been "reorienting" its business towards the faster growing and much less capital intensive ambulatory and revenue cycle management segments and away from capital intensive acute care segment. Rigg said Tenet is well positioned to self fund near-term capital commitments and believes the company's 2017 EBITDA guidance is achievable.
11/22/16
MZHO
11/22/16
DOWNGRADE
MZHO
Underperform
Tenet downgraded to Underperform from Neutral at Mizuho
Mizuho downgraded Tenet to Underperform citing premium valuation and lack of visibility on what will happen to ACA, Medicaid, and Medicare.
02/24/17
MZHO
02/24/17
UPGRADE
Target $22.8
MZHO
Neutral
Tenet upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Sheryl Skolnick upgraded Tenet to Neutral and raised the price target to $22.80 from $13 to reflect cost cutting initiatives and potential asset sales.
01/03/17
PIPR
01/03/17
INITIATION
Target $16
PIPR
Neutral
Tenet initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Sarah James initiated Tenet with a Neutral and a $16 price target.
UHS Universal Health
$121.81

-1.25 (-1.02%)

03/27/17
MZHO
03/27/17
UPGRADE
MZHO
Buy
Universal Health upgraded to Buy from Neutral at Mizuho
03/27/17
03/27/17
UPGRADE

Buy
Universal Health upgraded to Buy following ACA repeal failure at Mizuho
As previously reported, Mizuho upgraded Universal Health to Buy from Neutral with a $138 price target. Analyst Sheryl Skolnick said the failure of the GOP to move on ACA repeal out of the House, will result in the continuation of the important benefit of Medicaid expansion and without a near-or medium-term threat of block grants. Additionally, the analyst views Universal Health as undervalued given strong volumes and free cash flow.
04/04/17
DBAB
04/04/17
INITIATION
DBAB
Buy
Universal Health initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated Universal Health with a Buy rating and a $145 price target, citing the company's long-term track record and "pristine" balance sheet.
UNH UnitedHealth
$164.96

-0.6 (-0.36%)

04/05/17
DBAB
04/05/17
INITIATION
Target $183
DBAB
Buy
UnitedHealth initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Chris Rigg started UnitedHealth with a Buy rating and $183 price target. The company's transformation from a multi-line health insurer into a diversified healthcare services organization makes it a core holding, Rigg contends.
04/04/17
LEER
04/04/17
NO CHANGE
LEER
Higher Medicare Advantage rate boding positively for Managed Care, says Leerink
Leerink analyst Ana Gupte says that a final Medicare Advantage rate 20 bps higher than February advance rate notice bodes positively for Managed Care, in particular for Humana (HUM), WellCare (WCG), and UnitedHealth (UNH). The analyst is encouraged that the rate has moved modestly up, and sees this as directionally consistent with a more plan friendly Republican Administration.
03/27/17
COWN
03/27/17
NO CHANGE
COWN
Defeat of AHCA positive for Centene, Molina, WellCare, says Cowen
Cowen analyst Christine Arnold called Medicaid the "real winner" in the defeat of the American Health Care Act, or AHCA, and said the fact that Medicaid expansion under the ACA remains intact is a positive for Centene (CNC), Molina (MOH), and WellCare (WCG). Medicare Advantage is a moderate loser near-term, added Arnold, who notes that Humana (HUM), UnitedHealth (UNH) and other diversified insurers have exposure to MA.
04/03/17
PIPR
04/03/17
NO CHANGE
PIPR
Overweight
Piper reiterates Overweight on Hologic after UnitedHealth policy update
Piper Jaffray analyst William Quirk says UnitedHealth (UNH) updated its coverage policy today to now cover 3D tomosynthesis. With UnitedHealth following Aetna's (AET) lead, the analyst estimates that 3D tomo is now covered for 102.7M total lives. Incremental coverage of 3D tomo is a positive for 3D system adoption, Quirk tells investors in a research note. He reiterates an Overweight rating on Hologic (HOLX) and recommends investors buy the stock into 2018.
KND Kindred Healthcare
$7.75

-0.05 (-0.64%)

11/08/16
STFL
11/08/16
DOWNGRADE
STFL
Sell
Kindred Healthcare downgraded to Sell from Hold at Stifel
11/10/16
RBCM
11/10/16
DOWNGRADE
RBCM
Sector Perform
Kindred Healthcare downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Frank Morgan downgraded Kindred after the company lowered its fiscal 2016 guidance. Morgan says that the guidance cut was caused by pressures on the company's SNF segment. Morgan adds that the company's planned exit from its SNF business, along with regulatory pressures, will produce "significant uncertainties and likely bumpiness." He thinks that the stock could rebound in the near-term, but he expects it to subsequently be "range-bound" for "the next year or so." Target to $9 from $16.
11/08/16
STFL
11/08/16
DOWNGRADE
STFL
Sell
Kindred Healthcare downgraded on Q3 miss, guidance cut at Stifel
As noted earlier, Stifel downgraded Kindred to Sell from Hold. Analyst Chad Vanacore downgraded the stock based on the company's weaker than expected results and guidance reduction. Target to $5 from $10.
VTR Ventas
$65.06

-0.58 (-0.88%)

03/15/17
03/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Express Scripts (ESRX) downgraded to Underperform from Market Perform at Wells Fargo with analyst Peter Costa saying the shares do not reflect the 20%-40% earnings risk related to re-pricing of or losing the Anthem (ANTM) contract. The analyst also sees risk of market share losses related to Express' pharmacy benefit manager model. Costa cut his price target range for the shares to $52-$56 from $79-$85. 2. AMC Entertainment (AMC) downgraded to Underperform from Neutral at Credit Suisse with analyst Omar Sheikh saying 2017 will be a transition year with investments likely depressing cash flow. Over the long term, the analyst believes premium video on demand could be disruptive to the business models of exhibitors. He cut his price target for AMC shares to $26 from $34. 3. American Water (AWK) downgraded to Hold from Buy at HSBC with analyst Verity Mitchell citing the recent rally in the shares and the belief that rising interest rates are likely to be less supportive of a regulated utility that yields only 2.2% for 2017. The analyst keeps a $79 price target for the shares. 4. Citrix (CTXS) downgraded to Neutral on valuation at BofA/Merrill with analyst Kash Rangan citing valuation, and raised his price target to $91 from $87. 5. Ventas (VTR) downgraded to Sell from Neutral at Goldman with analyst Andrew Rosivach saying rising interest rates will meaningfully affect the company's ability to produce external growth. The analyst cut his price target for the shares to $56 from $70. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/15/17
GSCO
03/15/17
DOWNGRADE
Target $56
GSCO
Sell
Ventas downgraded to Sell from Neutral at Goldman
Goldman Sachs analyst Andrew Rosivach downgraded Ventas to Sell saying rising interest rates will meaningfully affect the company's ability to produce external growth. The analyst cut his price target for the shares to $56 from $70.
03/21/17
RHCO
03/21/17
INITIATION
Target $64
RHCO
Hold
Ventas initiated with a Hold at SunTrust
SunTrust initiated Ventas with a Hold and a $64 price target.
03/15/17
03/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with an Underweight at Cantor. 2. Pattern Energy (PEGI) initiated with a Neutral at Goldman. 3. Windstream (WIN) reinstated with a Neutral at JPMorgan. 4. ClearOne (CLRO) resumed with a Buy at B. Riley. 5. REV Group (REVG) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AET Aetna
$128.63

-0.45 (-0.35%)

03/27/17
CHLM
03/27/17
NO CHANGE
Target $28
CHLM
Buy
Craig-Hallum recommends buying Exact Sciences
Craig-Hallum analyst Bill Bonello continue to recommend purchase of Exact Sciences (EXAS) as Aetna (AET) coverage reinforces his view that the outlook is stronger than ever. After the latter published an updated colorectal cancer screening policy which now includes coverage of Exact Sciences' Cologuard, the analyst notes that Aetna was "one of the last major holdouts" from a commercial coverage standpoint. Bonello reiterates a Buy rating and $28 price target on Exact Sciences' shares.
03/28/17
ROTH
03/28/17
NO CHANGE
Target $26
ROTH
Buy
Aetna news should expand Exact Sciences Cologuard opportunity, says Roth Capital
Roth Capital analyst Chris Lewis notes that Aetna (AET) announced it has issued a positive coverage decision for Exact Sciences' (EXAS) Cologuard. Given Aetna's size, the analyst expects the positive development should "significantly" expand Cologuard's addressable market opportunity over time. He reiterates a Buy rating and $26 price target on Exact Sciences' shares.
04/05/17
DBAB
04/05/17
INITIATION
Target $135
DBAB
Hold
Aetna initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg started Aetna with a Hold rating and $135 price target.
ANTM Anthem
$164.99

-1.44 (-0.87%)

04/05/17
DBAB
04/05/17
INITIATION
Target $166
DBAB
Hold
Anthem initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg started Anthem (ANTM) with a Hold rating and $166 price target. The analyst assumes the Cigna (CI) deal does not close and thinks the stock will be range bound over the near-term until visibility improves.
03/10/17
COWN
03/10/17
NO CHANGE
Target $62
COWN
Outperform
Cowen sees coverage re-evaluations as positive for Sarepta
Cowen analyst Ritu Baral believes payors are still actively evaluating and re-evaluating coverage of Sarepta Therapeutics' Exondys 51. It appears that Anthem (ANTM), after an initial denial of coverage, has re-evaluated its decision on Exondys, Baral tells investors in a research note. She notes, though, that coverage discussions appear to be ongoing and amenable patients are still experiencing denials. The analyst sees the re-evaluations of coverage as positive for Sarepta. Baral has an Outperform rating on the shares with a $62 price target.
03/15/17
WELS
03/15/17
DOWNGRADE
WELS
Underperform
Express Scripts downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Peter Costa downgraded Express Scripts (ESRX) to Underperform saying the shares do not reflect the 20%-40% earnings risk related to re-pricing of or losing the Anthem (ANTM) contract. The analyst also sees risk of market share losses related to Express' pharmacy benefit manager model. Costa cut his price target range for the shares to $52-$56 from $79-$85.
04/04/17
COWN
04/04/17
NO CHANGE
Target $90
COWN
Outperform
Express Scripts weakness a buying opportunity, says Cowen
Cowen analyst Charles Ryhee believes Express Scripts (ESRX) shares overly discount the impact of Anthem's (ANTM) contribution and that the decision is an overhang on the stock. If Anthem stays with Express Scripts, the shares will react positively, and if they don't stay with them, shares will react positively anyway as the stock's multiple will gravitate more toward peer valuation, Ryhee tells investors. He reiterated his Outperform rating and $90 price target on Express Scripts shares.
CI Cigna
$150.41

-0.18 (-0.12%)

03/13/17
BOFA
03/13/17
INITIATION
Target $175
BOFA
Buy
Cigna assumed with a Buy at BofA/Merrill
BofA/Merrill analyst Kevin Fischbeck assumed coverage of Cigna with a Buy rating and $175 price target. The company's core business continues to improve, which will drive above average earnings growth in 2017, the analyst contends.
03/13/17
03/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BofA Merrill Lynch analyst Kevin Fischbeck assumed coverage of Cigna (CI) with a Buy rating and $175 price target. The company's core business continues to improve, which will drive above average earnings growth in 2017, the analyst contends. 2. Canaccord Genuity analyst Richard Close started Health Insurance Innovations (HIIQ) with a Buy rating and $28 price target. Deregulation under the Trump administration provides a favorable growth outlook for the company's insurance sales, the analyst said. 3. Jefferies analyst Philippe Houchois started Ferrari (RACE) with a Buy rating and $74 price target. 4. Baird analyst Mircea Dobre started John Bean Technologies (JBT) with an Outperform rating and $101 price target, while Wells Fargo analyst Allison Poliniak-Cusic started John Bean Technologies with an Outperform rating and $100-$102 price target range. 5. UBS analyst Brennan Hawken started E-Trade Financial (ETFC) with a Buy rating and $43 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/17
DBAB
04/05/17
INITIATION
Target $172
DBAB
Buy
Cigna initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Chris Rigg started Cigna with a Buy rating and $172 price target. The analyst thinks Cigna's consultative selling process is resonating with clients and that earnings expectations for the company are too low.
HUM Humana
$211.80

-1.19 (-0.56%)

04/05/17
DBAB
04/05/17
INITIATION
Target $216
DBAB
Hold
Humana initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg started Humana with a Hold rating and $216 price target.
03/30/17
03/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunoco (SUN) initiated with a Sell at Goldman. 2. CyberArk (CYBR) initiated with an Equal Weight at Morgan Stanley. 3. Humana (HUM) reinstated with an Outperform at Oppenheimer. 4. Qualys (QLYS) initiated with an Overweight at Morgan Stanley. 5. Alexion (ALXN), AveXis (AVXS), and Spark Therapeutics (ONCE) were initiated with a Buy at UBS, while Alnylam (ALNY) and BioMarin (BMRN) were initiated with a Neutral, and United Therapeutics (UTHR) was initiated with a Sell. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/30/17
OPCO
03/30/17
INITIATION
Target $236
OPCO
Outperform
Humana reinstated with an Outperform at Oppenheimer
Oppenheimer analyst Michael Wiederhorn reinstated Humana with an Outperform rating and $236 price target. The company has a "compelling opportunity to drive growth in the increasingly appealing Medicare Advantage business," Wiederhorn tells investors in a research note. The analyst believes the company's balance sheet should help create shareholder value.

TODAY'S FREE FLY STORIES

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCB

Anchor Bancorp

$24.75

-0.1 (-0.40%)

17:02
11/17/17
11/17
17:02
11/17/17
17:02
Hot Stocks
Anchor Bancorp announces stock repurchase program, 10b5-1 trading plan »

Anchor Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:58
11/17/17
11/17
16:58
11/17/17
16:58
Syndicate
Breaking Syndicate news story on Gulf Island Fabrication »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$31.09

0.59 (1.93%)

16:51
11/17/17
11/17
16:51
11/17/17
16:51
Hot Stocks
Mid Penn Bancorp, Scottdale shareholders approve merger »

Mid Penn Bancorp and The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALD

Callidus Software

$28.95

0.3 (1.05%)

16:49
11/17/17
11/17
16:49
11/17/17
16:49
Initiation
Callidus Software initiated at First Analysis »

Callidus Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:46
11/17/17
11/17
16:46
11/17/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

Piton Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

16:42
11/17/17
11/17
16:42
11/17/17
16:42
Hot Stocks
General Electric CEO acquires 60,000 common shares »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRE

Northstar Realty Europe

$14.20

0.05 (0.35%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Syndicate
Breaking Syndicate news story on Northstar Realty Europe »

Northstar Realty Europe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

FHN

First Horizon

$18.40

0.1 (0.55%)

, CBF

Capital Bank

$39.95

0.25 (0.63%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Hot Stocks
First Horizon, Capital Bank agree to sell two branches to Apex Bank »

First Horizon (FHN) and…

FHN

First Horizon

$18.40

0.1 (0.55%)

CBF

Capital Bank

$39.95

0.25 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$194.25

-0.75 (-0.38%)

16:32
11/17/17
11/17
16:32
11/17/17
16:32
Hot Stocks
Lennox executive sells 2,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TBNK

Territorial Bancorp

$30.99

0.21 (0.68%)

16:31
11/17/17
11/17
16:31
11/17/17
16:31
Hot Stocks
Territorial Bancorp declares special cash dividend of 30c per share »

Payable on December 20.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRTN

Triton International

$40.07

-0.77 (-1.89%)

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Hot Stocks
Triton International's Hanau sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.